- Home
- ADXN vs CVKD Comparison
ADXN vs CVKD Comparison
Compare ADXN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- CVKD
- Stock Information
- Founded
- ADXN 2002
- CVKD 2022
- Country
- ADXN Switzerland
- CVKD United States
- Employees
- ADXN N/A
- CVKD N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- ADXN Health Care
- CVKD Health Care
- Exchange
- ADXN Nasdaq
- CVKD Nasdaq
- Market Cap
- ADXN 11.3M
- CVKD 17.1M
- IPO Year
- ADXN N/A
- CVKD 2023
- Fundamental
- Price
- ADXN $10.30
- CVKD $15.24
- Analyst Decision
- ADXN Strong Buy
- CVKD Strong Buy
- Analyst Count
- ADXN 1
- CVKD 2
- Target Price
- ADXN $30.00
- CVKD $52.50
- AVG Volume (30 Days)
- ADXN 22.8K
- CVKD 59.6K
- Earning Date
- ADXN 11-11-2024
- CVKD 11-08-2024
- Dividend Yield
- ADXN N/A
- CVKD N/A
- EPS Growth
- ADXN N/A
- CVKD N/A
- EPS
- ADXN 0.05
- CVKD N/A
- Revenue
- ADXN $960,641.00
- CVKD N/A
- Revenue This Year
- ADXN N/A
- CVKD N/A
- Revenue Next Year
- ADXN N/A
- CVKD N/A
- P/E Ratio
- ADXN $1.75
- CVKD N/A
- Revenue Growth
- ADXN N/A
- CVKD N/A
- 52 Week Low
- ADXN $5.00
- CVKD $5.40
- 52 Week High
- ADXN $27.90
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- ADXN 54.08
- CVKD 60.90
- Support Level
- ADXN $10.04
- CVKD $11.19
- Resistance Level
- ADXN $10.81
- CVKD $15.93
- Average True Range (ATR)
- ADXN 0.59
- CVKD 1.36
- MACD
- ADXN 0.04
- CVKD 0.23
- Stochastic Oscillator
- ADXN 70.88
- CVKD 61.01
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.